NCT04489433 2025-12-18Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic MelanomaNovartisNo longer available
NCT04544202 2024-11-12Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical ResectionNovartisNo longer available
NCT03386071 2019-01-16Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With TrametinibJonsson Comprehensive Cancer CenterNo longer available
NCT02416232 2017-08-15Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous MelanomaGlaxoSmithKlineNo longer available